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Abstract
Background: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the
aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden
of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data
sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on
epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic
Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.
Methods: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY),
quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from
European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-
reviewed publications published between 2009 and 2019.
Results: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates
were mostly lacking. Available data were not always stratified by age and risk group, which is especially important
when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC.
Conclusion: This study provides an exhaustive overview of the available data sources and data gaps for the
estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD
studies and contribute to calculation of (P)VPDs BoD.
Keywords: Infectious disease, Elderly, Burden of disease, Vaccine, Public health
Background
In 2019, ageing adults (≥50 years) represented about 40%
of the population in the European Union (EU), and this
proportion is expected to reach 50% by 2025 [1–5]. This
rising demographic trend is expected to lead to a
growing demand for healthcare as infectious diseases in
ageing adults, especially those affecting the elderly (≥65
years), already place a significant health and economic
burden on individuals and societies [1, 6, 7]. Ageing
adults experience a natural decline in their immune re-
sponse, also called immuno-senescence [5, 6], increasing
their risk of contracting infectious diseases, as well as
their risk of a severe disease course. Ageing patients
often present with atypical symptoms, thereby compli-
cating the clinical diagnosis [8–10]. Moreover, for per-
sons living in elderly care institutions, close living
arrangements can further increase the risk of infection.
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Prevention strategies, and more specifically vaccin-
ation, are often a cost-effective way to decrease the inci-
dence of infectious diseases, thereby contributing to
healthy ageing [11–13]. Although effective vaccines are
already available to prevent some major infectious dis-
eases in ageing adults, such as influenza and pneumo-
coccal disease [1, 14], their vaccination coverage rates
remain relatively low in Europe [6]. This is likely due to
limited awareness of the adverse impacts on health aris-
ing from infectious diseases, and existing gaps in the
promotion of adult vaccinations by public health author-
ities [1, 6]. To guide decision-making about potential
prevention strategies for this age-group, it is essential to
understand the burden of disease (BoD) and to identify
existing data gaps.
In this context, the second Innovative Medicine Initia-
tive (IMI2) supported the Vaccines and InfecTious Dis-
eases in the Ageing PopuLation (IMI2-VITAL) project
[15], which aims to address the current challenges of
(potentially) vaccine-preventable diseases ((P)VPD) in
ageing adults in the EU/EEA. The project will provide
evidence-based knowledge on possible specific vaccin-
ation strategies to enhance healthy ageing.
We present here a comprehensive review of currently
available data sources in the EU/EEA for 2009–2019 to
calculate the BoD of (P)VPD in ageing adults and de-
scribe the data gaps.
Methods
Disease selection
We identified (P)VPD based on WHO summary informa-
tion [16] and input from project members. We subse-
quently selected diseases to review based on their relevance
for EU/EEA and the ageing adult population, and the
availability of a vaccine in at least phase 2 of clinical devel-
opment. This resulted in a list of seven infectious diseases:
influenza, varicella/herpes zoster, herpes simplex virus, nor-
ovirus, respiratory syncytial virus (RSV), Staphylococcus
aureus (S. aureus), extra-intestinal pathogenic Escherichia
coli (ExPEC), and pneumococcal pneumonia (PnPn). This
list was further narrowed down to diseases with a high BoD
and/or lack of BoD data. The ranking resulted in five
(P)VPD to be assessed on data sources for this review: nor-
ovirus, S. aureus, ExPEC, PnPn, and RSV.
National disease expert surveys
An online survey on BoD data was developed for
each of the selected (P)VPD and sent to disease ex-
perts from IMI2-VITAL participating countries
(Belgium, Denmark, Hungary, Italy, The Netherlands,
Norway and Spain). The experts were identified by
the IMI2-VITAL partners who aimed to adhere to the
European Centre for Disease Prevention and Control
(ECDC) national focal points. The parameters of
interest included summary measures (disability-ad-
justed life year (DALY), quality-adjusted life year
(QALY)), utility/disability, morbidity, mortality, anti-
microbial resistance (AMR), other pathogen-associated
and patient registry data.
The surveys, developed in Google Forms, were based
on case definitions described in Table 1 with a supple-
mentary example available in Additional file 1. The sur-
vey responses were summarised by listing the available
data for each BoD indicator by country.
Literature reviews
A literature review was conducted by searching the
MEDLINE database (via PubMed) for peer-reviewed
Table 1 case definitions used for the surveys of national disease experts









1. Norovirus infection: diarrhoea or vomiting or both in a 24-h period confirmed by a positive laboratory test (nucleic acid
amplification assay or antigen detection or electron microscopy) or




1. Non-bacteraemic PnPn: clinical symptoms consistent with pneumonia, with a positive pneumococcal urinary antigen test
(UAT) but a negative blood culture, or





1. Community based Acute Infection (ARI caused by RSV): sudden onset of at least one of the following symptoms: shortness
of breath; cough; sore throat and coryza and a laboratory confirmation with RSV, or
2. Hospital-based Extended Severe Acute RSV Infection (SARI caused by RSV): abovementioned symptoms with onset within
the last ten days, requiring hospitalisation and a laboratory confirmation with RSV. This could include severe lower respiratory
tract infections, like pneumonia.
Staphylococcus aureus
(S. aureus)
Invasive S. aureus infection: clinical symptoms consistent with bacteraemia or sepsis, and isolation of S. aureus from the blood
or other sterile site (synovial fluid, cerebrospinal fluid, pleural fluid, bronchoalveolar lavage, or from a sterile taken deep-
seated abscess).
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publications with data relevant to BoD calculations. A
search strategy was developed for each disease, con-
sisting of a common part across all diseases and a
disease-specific part (Additional file 2). The former
contained search terms on BoD parameters, age group
and the period of interest, while the latter contained
the name of the pathogen, clinical syndromes and re-
lated synonyms. The BoD parameters included sum-
mary measures (DALY, QALY, years of life lost
(YLL), years lived with disability (YLD) and Quality of
Life (QoL)), disability/utility, morbidity mortality and
AMR data. The period of interest was restricted to
the last 10 years (01/01/2009–23/05/2019), except for
PnPn, where only publications since 01/01/2012 were
included. The rationale was to exclude data reported
before large-scale paediatric use of more-valent
pneumococcal conjugate vaccines (PCV10/PCV13), as
this has impacted the BoD in the ageing population
due to indirect effects [17, 18].
The literature selection process and the number of
excluded publications by reason were documented
and presented in PRISMA flow-diagrams (Add-
itional file 3). Titles and abstracts of identified re-
cords were screened by one reviewer to identify
studies that fulfilled the selection criteria. Studies
were excluded if there was 1) No English abstract and
an irrelevant title, 2) No human subjects, 3) No rela-
tion to the disease of interest, 4) No new evidence
described (editorials, letters, case reports/series), 5)
No relevant data (this criterion was further specified
in each disease area according to the characteristics
of the disease in question, see definitions on the PRIS
MA flowcharts), 6) Only children, or 7) If the study
was conducted outside of Europe. A sample of 100
abstracts per disease was double-screened, and dis-
crepancies were discussed among reviewers. Data
from the selected publications were then extracted
using a uniform Excel table for all diseases. Based on
the available literature, summary tables were created
to list the countries for which BoD parameters were
available.
Results
Extra-intestinal pathogenic Escherichia coli
Survey
The Netherlands, Denmark and Norway use the pro-
posed case definition in their surveillance (Table 1). In
Italy, only a subset of laboratories within the European
AMR surveillance network (EARS-net) use this case def-
inition. Hungary uses a non-agent specific definition for
Hospital-Associated Bloodstream Infections (HA-BSI)
[19], Belgium and Spain do not collect ExPEC-specific
data. None of the countries reported summary BoD
measures (Table 2). Stratification by age-group and risk
factors was reported as possible in the six countries for
which morbidity data are available (Hungary, Denmark,
Norway, Italy, and The Netherlands). ExPEC-mortality
and sequelae data were rarely available. The latter could
only be retrieved in The Netherlands. All countries col-
lected AMR data.
Literature review
A total of 940 publications were identified in the litera-
ture review, of which 41 were included for data extrac-
tion covering eleven countries (Additional files 3 and 4).
Most publications came from the United Kingdom (UK)
(n = 9), Denmark (n = 6) and Spain (n = 4) (Table 3).
Additionally, seven publications included multiple coun-
tries for data extraction. Respectively, twelve and three
publications focused on E.coli bacteraemia and urosep-
sis. Sixteen studies provided general Bloodstream Infec-
tion (BSI) morbidity data. Only eight studies presented
E.coli bacteraemia incidence. Seven publications con-
cerned BSI caused by AMR E.coli strains. Several coun-
tries presented data on E.coli BSI mortality (Denmark,
Finland, Norway, Sweden and the UK) or AMR E.coli-re-
lated BSI mortality (Germany and Spain). A large Euro-
pean study reporting ICU-specific mortality data was
also identified. Many publications focusing on AMR
E.coli BSI were found. Two large AMR-focused surveil-
lance systems were identified (SENTRY and EARS-Net)
[20, 21]. Only one study reported DALYs for AMR
E.coli, and no study reported disability/utility weights,




Belgium, Italy and Spain use both the norovirus and syn-
dromic (acute gastroenteritis) case definitions in their
surveillance (Table 1). Denmark uses only the norovirus
case definition. The Netherlands collects aggregated la-
boratory surveillance data on norovirus. Hungary and
Norway collect data on norovirus outbreaks. The survey
results indicated that the majority of countries collected
norovirus morbidity data (6 out of 7), mortality data (4
out of 7), and hospitalisation data (4 out of 7) (Table 2).
In addition, Belgium, Denmark and the Netherlands esti-
mated DALYs specifically for norovirus.. However, only
a few countries assessed the level of under-reporting or
under-ascertainment (i.e. completeness) of morbidity
data, and morbidity and mortality data were rarely strati-
fied by age or risk factors. No country collected sequelae
data.
Literature review
The literature review yielded 371 publications, of which
24 were selected for data extraction (Additional files 3
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and 4). Data from eight countries were retrieved, mostly
from the Netherlands (n = 6), the UK (n = 6) and
Germany (n = 5) (Table 2). Four studies (from the UK
and the Netherlands) estimated DALYs based on inci-
dence data obtained via the population-based studies
Sensor [22] and IID2 (Infectious Intestinal Disease in the
community study) [23, 24]. Morbidity data were re-
trieved in 24 publications, half of them describing
pathogen-specific data, in most cases stratified by age.
Sequelae data were identified in three syndromic data
studies. Norovirus and syndromic disease mortality data
were identified in eight and three studies, respectively.
Pneumococcal pneumonia
Survey
Spain and Italy use the non-bacteraemia PnPn case def-
inition in their surveillance, whereas the other countries
use only the all-cause pneumonia case definition (Table
1). Overall, PnPn-specific BoD data is lacking, as no
country collected summary BoD data, and only Spain
and Italy reported PnPn-morbidity and mortality data
(Table 2). On the other hand, more data was available
for all-cause pneumonia; Belgium and the Netherlands
reported that DALY and/or QALYs have already been
calculated or could be calculated for all-cause pneumo-
nia. All-cause pneumonia incidence and hospitalisation
data are available in most countries, and mortality data
are available in the Netherlands, Belgium and Hungary.
Literature review
A total of 784 publications were identified, of which 40
were included for data extraction (Additional files 3 and
4). Most studies were conducted in Spain (n = 9), the
Netherlands (n = 8), the UK (n = 7) and Italy (n = 5)
(Table 2). Only two studies reported QALYs; both were
based on the CAPITA study from the Netherlands on
all-cause pneumonia [25, 26]. Two studies from France
and Switzerland determined the QoL for all-cause pneu-
monia [27, 28]. For most studies, the incidence was
based on hospital discharge data, either for all-cause
Table 2 Data sources available to capture (P) VPD burden of disease (BoD) based on national disease expert surveys: Countries with
available data sources
Indicator ExPEC NoV PnPn RSV S.aureus
Summary BoD
DALY not available BE, NL, DK NL BE, DK BE
QALY not available not available BE, NL not available not available
Disability/utility
utility weights not available not available NL not available not available
disability weights not available not available not available not available not available
Morbidity
incidence/prevalence HU, DK, IT, NO, NL BE, DK, ES, HU, IT, NL BE, ES, HU, IT NL, NO BE, NL, ES, DK, IT BE, HU, NL, DK, IT
serotype data NA NA ES, IT NA NA
attributable fraction NA NA BE, NL NA NA
sequelae NL not available not available DK NL, ES, DK
disease duration DK, NO ES, NL not available BE, ES, DK ES
hospitalization need HU, DK, IT, NO BE, ES, HU, NL BE, HU, NL BE, NL, ES, DK BE, HU, ES
hospitalization duration HU, DK, IT, NO BE, ES, HU, NL BE, NL BE, NL, ES, DK BE, HU, ES
stratification age/RF HU, IT, NL, NO DK, HU BE, ES, HU, IT, NL, NO BE, NL, ES, DK BE, HU, ES, NL, IT
completeness assessment HU BE, NL BE, NL NL HU, ES, DK
Mortality
mortality NO, IT BE, DK, ES, HU BE, ES, HU, IT, NL NL, BE, ES, DK ES
serotype data NA NA NA NA DK
case-fatality rate not available not available BE, HU BE, ES, DK DK
stratification age/RF NO HU BE, ES, HU, IT, NL BE, ES
Antimicrobial resistance DK, HU, IT, NL, NO NA NA NA BE, HU, NL, NO, ES, DK, IT
Other pathogen-associated data DK, HU, NL, NO NA NA NA BE, HU, DK
Patient registry NA NA NA NL, ES NA
Abbreviations: NoV norovirus, PnPn Pneumococcal pneumonia, RSV Respiratory Syncytial Virus, S.aureus Staphylococcus aureus, ExPEC Extra-intestinal pathogenic
Escherichia coli, BE Belgium, DK Denmark, ES Spain, HU Hungary, IT Italy, NL the Netherlands, NO Norway; NA Not applicable
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pneumonia or PnPn. Incidence data on outpatients with
all-cause pneumonia were only reported for France, the
Netherlands and Belgium. Serotype-specific PnPn inci-
dence data were available in three studies. Several stud-
ies reported the attributable fraction for pneumococci
using hospital discharge data. Most studies reported age
stratification data and half of them reported data for risk




Case definitions and methods to ascertain RSV cases dif-
fer widely by country (Table 1). In Belgium and Spain,
laboratory testing is usually conducted only in a selec-
tion of hospitalized cases. In the Netherlands, while a
subset of ARI cases undergoes laboratory testing for
RSV and real-time SARI surveillance is being piloted, no
official laboratory confirmation is needed for applying
ICD-10 codes in hospitalized cases. Many hospitals in
Norway conduct influenza like illness (ILI) surveillance
with RSV and influenza panel testing, which results in
RSV-positivity among ILI cases. Under-ascertainment
and underreporting may bias the official frequency esti-
mates as the completeness of reported frequency data
are not assessed in any of the countries (Table 2). The
only exception might be the Netherlands, where efforts
have been made to assess data completeness for RSV
cases identified in primary care. RSV sequelae data are
available from Denmark, and are also currently being
studied in the Netherlands, in the context of the RESC
EU (Respiratory Syncytial virus Consortium in Europe)
project [27]. Spain has reported that hospital records
could be used as a possible source of sequelae data. As
Table 3 Data sources available to capture (P) VPD based on literature reviews: Number of references and countries with available
data sources
Indicator ExPEC NoV PnPn RSV S.aureus
n Countries n Countries n Countries n Countries n Countries
Summary BoD
data
1 EU 3 NL, UK 2 NL 1 world 0




33 AT, CH, DE, EU,
DK, ES, FI, FR, IT,
NO, SE, UK
24 CH, DE, ES,
FR, IT, NL,
SE, UK
17 DE, ES, FI,
FR, IT, PO,
NL, SE
36 BE, CH, DE, EU, ES,
FR, GR, HU, NL, PO,
SE, UK, world
51 BA, CH, DE, DK, ES, EN, EU, FI, FR, GE, GR,
IE, IS, IT, ME, MK, NL, NO, PO, RO, RS, SC,
SE, TR, XK
NSS and AFa 14 BE, ES, IT,
NL, SE, UK
11 BE, CH, EU, FR, UK,
world
sequelae 4 AT, CH, DE, DK,
FR, UK




0 8 DE, ES, FR,
IT, NL, UK
4 BE, FR, NL,
UK
1 world 3 DK, IL, SC
hospitalization
need
0 14 CH, DE, FR,
IT, NL, SE,
UK
2 BE, FR 15 CH, ES, EU, FR, SE,
UK, world
11 AT, DE, DK, HR, IS, IT, NO, SE
hospitalization
duration
15 AT, DE, DK, EU,
SE, UK
4 DE, NL, SE 13 ES, FR, IT,
NL, UK
7 CH, ES, EU, FR 27 AT, BE, CH, DE, DK, ES, FI, FR, GR, HR, IE,
NO, RO, SC, SE, TR
Age
stratification
19 CH, DK, DE, EU,
FI, FR, IT, NO, SE,
UK
23 CH, DE, ES,
FR, IT, NL,
SE, UK
25 BE, ES, FI,
FR, IT, NL,
PO, SE
27 BE, CH, DE, ES, EU,
FR, GR, HU, NL, PO,
SE, UK, world






24 AT, DE, DK, ES,
EU, FI, FR, NO, SE,
UK
10 DE, NL, SE,
UK
75 AT, BE, CH, DE, DK, EN, ES, FI, FR, HR, IE,
IL, IS, NO, SC, SE, TR
case-fatality
rate
5 EU, FI, NO, UK 2 DE, NL 13 DE, ES, FR,
IT, NL, SE,
UK
12 CH, ES, EU, FR, NL,
SE, UK, world
10 DK, FI, FR, IL, NO, TR
Antimicrobial
resistance
26 DE, DK, ES, EU, FI,
FR, IT, UK
NA 1 PT NA 63 AT, BA, BE, CH, DE, DK, EN, ES, EU, FI, FR,
GE,GR,IE, IL, IS, IT, ME, MK, NL, NO, PO, PT,
RO, RS, SC, SE,TR, XK
Abbreviations: NoV norovirus, PnPn Pneumococcal pneumonia, RSV Respiratory Syncytial Virus, S.aureus Staphylococcus aureus, ExPEC Extra-intestinal pathogenic
Escherichia coli, AT Austria, BA Bosnia and Herzegovina, BE Belgium, CH Switzerland, DE Germany, EN England, DK Denmark, ES Spain, EU Europe, FI Finland, FR
France, GE Georgia, GR Greece, HR Croatia, IE Ireland, IL Israel, IS Iceland, IT Italy, MK Macedonia, NL the Netherlands, ME Montenegro, NO Norway, PO Poland, PT
Portugal, RO Romania, RS Serbia, SC Scotland, SE Sweden, TR Turkey, UK United Kingdom, XK Kosovo; aNSS and AF: non-specific syndrome and attributable fraction
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several countries use SARI case definitions for RSV
(Belgium, Spain, the Netherlands, Denmark), there are
available data on hospitalisations and RSV-specific mor-
tality. In Belgium, sentinel hospitals report case-fatality
and RSV-SARI mortality data, which can be stratified by
age and risk groups. There are also case-fatality data in
Spain, but only for younger age-groups and for a subset
of cases which undergo laboratory testing.
Literature review
The literature search yielded a total of 711 publications,
of which 46 were included in the data extraction (Add-
itional files 3 and 4). The majority of studies originated
from the UK (n = 12), followed by Sweden (n = 4),
France (n = 3), Poland (n = 3), Spain (n = 3), Germany
(n = 2), Greece (n = 2), the Netherlands (n = 2),
Switzerland (n = 2), and Belgium (n = 1) (Table 2). In
the literature review, the most widely used case defini-
tions for sampling are based on ILI or ARI cases, or
both. Although one article reported age-specific DALYs
due to hospitalised lower or upper respiratory tract
infections (LRTIs and URTIs) caused by RSV, no study
described country-specific summary BoD estimates. In a
study by Shi et al. [28], simple BoD data (RSV incidence,
hospital admission rates, RSV positivity among hospita-
lised ARI cases and hospital case fatality ratios for RSV)
were estimated for industrialised vs developing coun-
tries, but no European-level data were described. Age
stratification and risk factor data (co-morbidities, such
as cardiopulmonary and cardiovascular diseases), im-
munocompromised health status, and seasonality were
widely reported in publications. Publications analysing
RSV surveillance data in the Netherlands and the UK
contained robust data on RSV-attributable mortality.
Case fatality rates were estimated in literature reviews
performed in French and Swedish hospitals [28, 29].
Staphylococcus aureus
Belgium, Denmark, Italy, the Netherlands, Norway and
Spain reported using the abovementioned S.aureus case
definition in their surveillance (Table 1). Hungary uses
the official non-specific ECDC case definition of HAI,
including the one for BSI [19]. Only Belgium reported
that DALYs could be calculated, although only for gen-
eral nosocomial infections but not for those which are
pathogen-specific (Table 2). None of the surveyed coun-
tries collect disability/utility weights. All countries, ex-
cept for Norway, have S.aureus incidence data available
or data which is easily retrievable and can be stratified
by risk factors. Several countries stated that they collect
sequelae and hospitalisation data. Very few countries
collect mortality data, while all countries collect AMR
data. Additionally, some countries collect non-BSI data,
such as S.aureus pneumonia and surgical site infection
cases.
Literature review
The literature search yielded 185 publications, of which
101 publications remained for data extraction after full-
text review (Additional files 3 and 4). Most publications
came from Denmark (n = 14), followed by Spain (n =
13), Germany (n = 9), England (n = 8), France (n = 7),
and Finland (n = 6). Two large European surveillance
systems were identified: the EARS-Net [20], and the
Central Asian and Eastern European Surveillance of
Antimicrobial Resistance (CAESAR) [29]. Both collect
data on blood cultures and AMR, which can be used to
calculate the incidence of S.aureus bacteraemia. EARS-
Net also allows age and gender stratification (Table 2).
None of the publications reported summary BoD mea-
sures. Incidence data could be extracted from 51 publi-
cations. In most cases, data were stratified by age.
Sequelae and hospitalisation data were often retrievable.
Disease duration was only reported in three studies. In
total, 75 studies reported on S.aureus-specific or all-
cause mortality. Many publications included risk factor
analyses related to mortality data. Almost all publica-
tions reported AMR in S. aureus infections.
Discussion
This review provides a comprehensive overview of the
available data sources and gaps for estimating BoD for
five priority (P)VPD in ageing adults in the EU/EAA.
Our expert surveys reveal that morbidity data are gen-
erally available for the diseases of interest. Furthermore,
the majority of countries collect mortality data for noro-
virus, PnPn and RSV, or for the associated syndromic
disease, such as acute gastroenteritis. These results are
corroborated by the results of the literature review, espe-
cially for S.aureus, ExPEC and RSV.
We found that summary BoD estimates, such as
DALYs and QALYs, are rarely available for the five dis-
eases. These summary measures are particularly valuable
for understanding the health impacts from a specific
(P)VPD in relation to other health conditions that affect
ageing adults [30]. Additionally, some parameters are
missing, such as the disability weights (DWs) needed to
calculate summary BoD estimates. DWs indicate the se-
verity of illness for a given non-fatal health outcome and
are typically based on the preferences of a panel of pa-
tients or medical experts that rates the relative undesir-
ability of hypothetical health outcomes [31, 32]. Since
DWs can depend on the cultural values and distribution
of health conditions that are specific to the setting in
which they are elicited, their valuation should be ideally
based on elicitation panels specific for the population of
interest [33]. However, in practice, the analysts make use
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of large databases of elicited DWs covering a wide range
of diseases/health conditions such as those produced for
the Global Burden of Disease study [34, 35].
Another important data gap is the overall absence of
completeness assessments of morbidity data. Given that
population-based disease incidence and/or prevalence data
are the central components of summary BoD measures, it
is fundamental to assess the validity of these parameters.
Notwithstanding the high quality of current EU infectious
disease surveillance systems, underestimation is known to
be a common issue in surveillance data. Its magnitude
may vary depending on the disease, country, time period,
and patient characteristics, and this variation can be due
to various factors such as differences in healthcare-seeking
behaviour, case management, and surveillance systems
[36–38]. Estimates of underestimation may be obtained,
for example, by comparing passive surveillance system
data to population-based survey data. Several methods are
available to adjust BoD input data and thus estimate true
incidence [30].
Moreover, morbidity/incidence data were not system-
atically stratified by age and risk group. The lack of age-
specific parameters that are needed for accurate DALY/
QALY computation represents a critical data gap in the
context of ageing adults. Kristensen et al. [39] studied
BoD in ageing adults for four vaccine-preventable dis-
eases and pinpointed that more precise BoD estimates
could be obtained by specifying age-specific, rather than
‘age-agnostic’, indicators (i.e. overall values). It is note-
worthy that stratification on age is also important for
transition probabilities (e.g., the risk of developing com-
plications following acute infection) and is expected to
be larger in ageing adults, but these were not investi-
gated in our review.
Although it is preferable to rely on country-specific
data to estimate BoD, estimates for some parameters can
be extrapolated from another country if no country-
specific data are available. For example, case-fatality
rates from one country may be applicable to other coun-
tries with similar health care systems. However, unlike
case-fatality rates, incidence data usually depend greatly
on the country, and therefore, country-specific incidence
estimates are critical for BoD estimates.
Although we have seen that morbidity data are
widely available, these data might not always be
pathogen specific. For (P)VPDs, such as PnPn or nor-
ovirus, laboratory confirmation and pathogen-specific
incidence data are currently scarce in EU/EEA, and,
consequently, it might be challenging to estimate BoD
for these pathogens. In this case, data on the inci-
dence of a clinically-defined set of symptoms or clin-
ical syndrome (e.g. pneumonia, gastroenteritis, etc.)
need to be first attributed to the responsible patho-
gen(s), usually by resorting to an attributable fraction
obtained from the literature, or otherwise estimated.
For PnPn and norovirus, more such data are needed
to accurately estimate the BoD of (P)VPDs for Euro-
pean countries.
For ExPEC, which is usually a hospital-detected infec-
tion, the attribution of BoD to the infection or the pa-
tient’s underlying condition poses an additional
challenge for the estimation of BoD that needs to be
handled. The true ExPEC infection incidence must be
extrapolated from available observed cases. Indeed,
infections in ageing adults are often associated with co-
morbidities, and thus, are reported as secondary diagno-
ses in hospital care [7].
Based on studies including outpatient PnPn, the bur-
den of PnPn is underestimated when using only hospita-
lised patient data [40, 41]. Therefore, the identified lack
of data on outpatient pneumonia should be taken into
account, and assessments of the degree of under-
reporting and under-ascertainment of the incidence data
are also needed. Furthermore, there is a lack of serotype-
specific data, which is mainly due to methodological
challenges. As long as pneumococcal vaccines do not
cover all serotypes, the BoD for the vaccine-preventable
part of all PnPn can only be estimated with available
serotype-specific data.
In the case of ExPEC and S.aureus, incidence and
mortality data are available but are often restricted to re-
sistant strains. Also, summary BoD measure estimates
might be underestimated because patients infected with
drug-susceptible strains are not included in the
calculations.
The main limitation of our study is that not all
EU/EEA countries were covered by the disease ex-
pert survey. Also, the survey responses were not for-
mally validated, even though the results were shared
and discussed within the IMI2-VITAL project Con-
sortium. In addition, although the extended literature
review allowed us to capture peer-reviewed litera-
ture, only a limited and selected amount of grey lit-
erature was covered in our study. The literature
reviews were restricted to English language publica-
tions, and in consequence, we may have missed
some important data sources. Finally, the disease
outcome trees, the duration of possible sequelae, and
transition probabilities between health outcomes
were not considered in our study, although these pa-
rameters would also be needed to compute summary
BoD measures.
Conclusions
Despite the fact that several methodological tools are
available to overcome at least some of the data gaps
identified, the results of this review have highlighted
the need for more BoD studies to be conducted. Our
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findings may guide future studies towards specific
(P)VPDs, countries and parameters for which infor-
mation is currently lacking. Furthermore, all the data
retrieved can be used to find references for specific
BoD parameters. This information will be useful for
the remainder of the IMI2-VITAL project, but may
also be used to inform other BoD studies on (P)VPD.
In addition, this study provides a framework that can
be easily adapted to other vaccine-preventable dis-
eases in the future.
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